Cori Clinical
AI platform for clinical trial development, connecting decisions, documents, and costs from design to first patient in.
Website: https://www.cori-clinical.com/
Cover Block
PUBLIC
| Field | Value |
|---|---|
| Name | Cori Clinical |
| Tagline | AI platform for clinical trial development, connecting decisions, documents, and costs from design to first patient in [Cori Clinical, retrieved 2026] |
| Headquarters | London, United Kingdom [StartupSeeker, retrieved 2026] |
| Founded | 2025 [StartupSeeker, retrieved 2026] |
| Stage | Seed [PitchBook, retrieved 2026] |
| Business model | SaaS |
| Industry | Healthtech |
| Technology | AI / Machine Learning |
| Geography | Western Europe |
| Growth profile | Venture Scale |
| Founding team | Co-Founders (2) |
| Funding label | Seed |
Links
Public sources
- Website: https://www.cori-clinical.com/
Executive Summary
PUBLIC Cori Clinical is building an AI software platform for clinical trial setup, focused on the document-heavy stretch from protocol design through initial regulatory submissions to first patient in, and it merits investor attention because the company is targeting a slow, expensive workflow where process friction is well understood but modern software penetration still appears uneven [Cori Clinical, September 2025] [Cori Clinical, retrieved 2026] [Breega, July 2026]. The company was founded in 2025 in London by Jorn Jansen Schoonhoven and Patricio Fernandez Weisson, who position the business around a simple thesis: clinical development has adopted new science faster than it has modernized the operating layer that turns trial plans into executable study start-up packages [Cori Clinical, September 2025] [Cori Clinical, retrieved 2026].
The product claim is specific enough to be interesting. Cori says it connects decisions, documents, and costs in one workspace, reviews trial documentation against regulatory and quality requirements, and tracks dependencies across protocol, geography, and submission materials while keeping human judgment in the loop [Cori Clinical, retrieved 2026] [LinkedIn, retrieved 2026]. If that workflow logic proves reliable in production, the differentiation would likely rest less on a generic model layer and more on how well the product handles compliance-sensitive trial documentation and cross-document consistency.
The founding team is the clearest public strength. According to company materials, Schoonhoven previously worked in data science roles at Amazon and IBM and later invested in AI startups at Octopus Ventures, while Fernandez Weisson previously held data science leadership roles at Evinova within AstraZeneca and at Sanofi [Cori Clinical, retrieved 2026] [Cori Clinical, September 2025] [LinkedIn, retrieved 2026]. Cori also highlights clinical operating depth through Emma Ogburn, PhD, its Chief Clinical Officer, whom the company describes as bringing more than 20 years of global trial experience [Cori Clinical, retrieved 2026].
The financing picture is still thin in public sources. Cori publicly identifies Heartfelt Capital and Bynd Venture Capital as investors, and a third-party profile reports an investment range of $108K to $432K from Heartfelt Capital, but no confirmed public round announcement, amount, or valuation was surfaced in the reviewed materials [PitchBook, retrieved 2026] [FundraisingFox] [Cori Clinical, retrieved 2026].
Over the next 12 to 18 months, the key watch items are straightforward: whether Cori converts product positioning into named customer proof points, whether hiring activity broadens beyond the July 2026 Senior AI Engineer posting, and whether the company discloses a priced seed round or other financing with enough detail to benchmark execution against peers [Breega, July 2026] [Cori Clinical, retrieved 2026]. For now, the case rests on a credible team and a plausible workflow wedge, with diligence still needed on customer adoption, integration depth, and evidence that the product can move from promising narrative to repeatable deployment.
Company-stated, unverified -- This section relies materially on company-owned sources, with limited independent corroboration from LinkedIn, Breega, PitchBook, and FundraisingFox.
Taxonomy Snapshot
| Axis | Value |
|---|---|
| Stage | Seed |
| Business Model | SaaS |
| Industry / Vertical | Healthtech |
| Technology Type | AI / Machine Learning |
| Geography | Western Europe |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (2) |
| Funding | Seed |
How the Company Got Here
PUBLIC
Cori Clinical is a London-based startup founded in 2025, focused on clinical-trial development software rather than discovery or patient-facing care delivery [Cori Clinical, retrieved 2026]. The company’s public framing is narrow enough to matter: it is building an AI platform intended to connect clinical decisions, documents, and costs across the stretch from trial design to first patient in, a workflow that remains document-heavy and compliance-sensitive for sponsors and CROs [Cori Clinical, retrieved 2026] [Cori Clinical, September 2025].
The public record on legal entity details is thin, so the cleaner read is chronological. Cori introduced itself publicly in 2025 with a launch post that set the initial scope from protocol development through regulatory submissions and first patient in, and its later website language continues to emphasize regulatory and administrative workflow automation with human oversight retained [Cori Clinical, September 2025] [Cori Clinical, retrieved 2026]. By July 2026, the company was publicly recruiting a Senior AI Engineer, which is a modest but concrete signal that product build-out was still in progress after launch [Breega, July 2026].
The founding story also rests mostly on company-published materials, but the pieces are at least directionally consistent. Cori names Jorn Jansen Schoonhoven and Patricio Fernandez Weisson as co-founders in its public materials, and the launch announcement presents the company as an attempt to apply AI to the operational bottlenecks of trial startup rather than to the science of molecule discovery itself [Cori Clinical, retrieved 2026] [Cori Clinical, September 2025]. That distinction matters because it places Cori in a software budget and workflow category where adoption may depend less on novel models than on process fit, auditability, and regulatory coherence.
Company-stated, unverified -- This section relies primarily on company website materials, with one corroborating public job posting from Breega.
Product and Technology
MIXED
The product story is narrower than the broad "AI for clinical trials" label suggests, and that narrower scope is the useful one to focus on. Cori Clinical describes its platform as a workspace for sponsors and contract research organisations that connects clinical decisions, documents, and costs from trial design through first patient in, with the initial workflow centered on protocol development, initial regulatory submissions, and related startup tasks [Cori Clinical, retrieved 2026] [Cori Clinical, September 2025]. The company also says the system automates regulatory and administrative workflows while keeping human control in the loop, which implies an assistive operating model rather than a fully autonomous one [Cori Clinical, retrieved 2026].
The public product detail that matters most is how Cori says the software handles trial documentation. On its website and LinkedIn materials, the company says the platform reviews documents against regulatory, quality, GxP, and patient-centric compliance requirements, tracks interdependencies across documents, adapts to protocol, geography, and study design, and flags alignment gaps intended to reduce inconsistency and manual rework [Cori Clinical, retrieved 2026] [LinkedIn, retrieved 2026]. A July 2026 job posting broadens that framing slightly, describing coverage across trial startup research, design, authoring, review, and amendments, but that wording still sits within the same document-heavy pre-enrollment workflow rather than later-stage trial operations [Breega, July 2026].
What remains less settled is the technical substrate behind those claims. No verified public demo, architecture disclosure, or independent product review in the provided source set establishes model choices, deployment model, validation framework, or integrations, so any deeper stack discussion would be conjecture. The clearest public signal is organizational rather than technical: Cori is hiring a Senior AI Engineer, which supports the view that core model and workflow capabilities are still being actively built or expanded [Breega, July 2026].
Company-stated, unverified -- This section relies primarily on company website, LinkedIn, and job-posting claims, with no independent product verification in the cited public sources.
Where the Demand Sits
PUBLIC
Clinical-trial operations has become a more relevant software market because sponsors are still trying to compress startup timelines while the paperwork, review burden, and compliance expectations around trial initiation keep expanding, which is the specific bottleneck Cori says it targets [Cori Clinical, September 2025] [Cori Clinical, retrieved 2026].
The evidence base here is thin on formal market sizing, so the market has to be framed through the workflow Cori is addressing rather than through a clean TAM model. Public company materials consistently position the product around protocol development, regulatory submissions, and the path to First Patient In, with sponsors and CROs as the primary buyers [Cori Clinical, September 2025] [Cori Clinical, retrieved 2026]. That places Cori in the clinical-development software stack rather than in discovery, patient recruitment, or site operations, even if those categories sit next to it in the broader trial technology budget [Breega, July 2026] [Cori Clinical, retrieved 2026].
Demand drivers are also more legible than market size. Cori's own framing is that trial startup remains document-heavy and interdependent, with decisions, costs, and submissions linked across multiple artifacts, and that errors or inconsistencies slow execution [Cori Clinical, retrieved 2026] [LinkedIn, retrieved 2026]. If that framing is directionally right, the budget case for software is less about replacing headcount and more about reducing cycle time, rework, and compliance friction before a study reaches its first enrolled participant [Cori Clinical, September 2025] [Breega, July 2026].
The adjacent markets matter because buyers may not budget this as a stand-alone line item at first. In practice, Cori appears to touch document authoring, regulatory workflow, clinical operations coordination, and parts of eTMF or broader clinical-trial management processes, based on how it describes connecting documents, workflows, and review steps in a single workspace [Cori Clinical, retrieved 2026] [Breega, July 2026]. That is potentially useful positioning, but it also means the company may sell into an existing software stack rather than into an empty category, which tends to lengthen enterprise evaluation cycles.
Regulatory and macro forces cut both ways. Cori repeatedly emphasizes compliance, human control, and review against regulatory, quality, GxP, and patient-centric standards, which suggests the company understands that clinical-development buyers will be cautious about AI touching submission-grade material [Cori Clinical, retrieved 2026]. The same caution can support demand if teams want software that preserves auditability and consistency, but it can also slow adoption if validation requirements rise faster than procurement urgency.
| Market lens | Public evidence | Implication for Cori |
|---|---|---|
| Core workflow | Trial design through initial regulatory submissions and up to First Patient In [Cori Clinical, September 2025] | Focuses the product on a narrow but operationally material phase of clinical development |
| Primary buyers | Sponsors and CROs [Cori Clinical, September 2025] [Cori Clinical, retrieved 2026] | Sales motion likely runs through clinical operations, regulatory, or trial startup teams |
| Problem type | Interdependent documents, decisions, and costs in one workspace [Cori Clinical, retrieved 2026] | Value proposition rests on coordination and error reduction more than model novelty |
| Adjacent budgets | Research, design, authoring, review, and amendments in trial startup [Breega, July 2026] | Category boundaries may blur with clinical operations and regulatory software |
The table points to a market that is real at the workflow level, but still weakly defined in public as a distinct software category. For investors, that usually means product relevance can be easier to argue than market size, at least until independent customer adoption data appears.
Company-stated, unverified -- This section relies primarily on company materials and a job posting, with no independently sourced market-sizing report or named third-party demand dataset in the available evidence.
Competitive Landscape
Positioning
MIXED Cori Clinical is positioning itself not as a full clinical-development suite, at least in the public record, but as a focused workflow layer for the trial-startup bottleneck between protocol design and first patient in [Cori Clinical, September 2025] [Cori Clinical, retrieved 2026].
That positioning matters because the practical alternatives are broader than a normal startup-versus-startup frame suggests. On one side sit incumbent pharma technology stacks and service-heavy operating models inside sponsors and CROs, where document authoring, regulatory submission prep, review cycles, and budget coordination are often spread across internal teams, legacy systems, and outsourced processes rather than concentrated in one purpose-built application [Cori Clinical, September 2025] [Breega, July 2026]. On the other side sit adjacent healthtech platforms tied to large biopharma ecosystems, including Evinova, which is relevant here because Cori co-founder and CTO Patricio Fernandez Weisson is identified in public sources as a former data science leader there [Cori Clinical, retrieved 2026] [Patricio Fernandez Weisson on LinkedIn: Lead Data Scientist]. The result is a competitive field defined less by one obvious direct rival and more by substitution risk from established enterprise workflows, internal tooling, and broader trial-operations platforms.
The company’s clearest edge today appears to be team-market fit around a narrow pain point, not scale or distribution. Cori says its platform connects clinical decisions, documents, and costs in one workspace, reviews documentation against regulatory and quality requirements, and preserves human control rather than removing expert judgment [Cori Clinical, retrieved 2026]. That is a credible wedge for regulated buyers if the product reduces rework across protocol, submission, and startup documentation. The durability of that edge is less clear. Much of the public differentiation rests on product claims from company materials, while the more durable moats in this category, such as embedded customer workflows, proprietary trial-document datasets, validated compliance performance, and reference accounts, are not yet publicly evidenced [Cori Clinical, retrieved 2026] [LinkedIn, retrieved 2026].
Where Cori looks most exposed is go-to-market reach and proof of commercial adoption. The public sources reviewed do not verify named customers, paid deployments, or formal commercial partnerships, while larger adjacent players can often sell into existing pharma relationships or package startup tooling into broader offerings [Cori Clinical, retrieved 2026] [LinkedIn, retrieved 2026]. Evinova is the most concrete named comparator in the source set because it combines domain relevance with AstraZeneca lineage through Fernandez Weisson’s background [Patricio Fernandez Weisson on LinkedIn: Lead Data Scientist]. Even if Evinova is not pursuing the exact same workflow boundary, it illustrates the kind of better-capitalized, enterprise-legible alternative that can compress a young company’s room to expand.
The most plausible 18-month scenario is a split market in which point solutions win only if they show measurable workflow compression in live programs. Cori is the winner if sponsors and CROs increasingly prefer specialist tools that can sit across fragmented startup processes without forcing a rip-and-replace of existing systems, particularly if its founding team converts prior pharma and platform experience into early design-partner relationships [Cori Clinical, September 2025] [Cori Clinical, retrieved 2026]. Evinova is the winner if buyers decide that vendor consolidation, integration depth, and enterprise credibility matter more than startup speed. Cori is the loser if the category shifts toward bundled procurement before it has publicly visible reference customers or a wider distribution channel.
Opportunity
Upside case
PUBLIC The prize here is not a better writing tool for trial teams, it is a credible shot at becoming the operating layer that sponsors and CROs use to move from protocol design to first patient in, a part of clinical development where document sprawl, regulatory complexity, and coordination delays are unusually expensive if a product can cut cycle time without breaking compliance assumptions [Cori Clinical, September 2025] [Cori Clinical, retrieved 2026].
The headline opportunity is to own the trial-startup workflow before data capture and site execution begin. Cori is not presenting itself as a general-purpose clinical AI vendor. Its public materials stay focused on the setup phase, connecting decisions, documents, and costs in one workspace, with initial coverage from protocol development through regulatory submissions and first patient in [Cori Clinical, September 2025] [Cori Clinical, retrieved 2026]. That focus matters because the wedge is narrow enough to ship against and broad enough to matter: if a team becomes system-of-record for protocol-linked documents, review logic, and submission readiness, it can sit close to the operational bottleneck that determines when a trial actually starts.
The path from reachability to scale still rests on company claims, so the upside case has to be framed carefully. Even so, two public signals make the outcome more than aspirational. First, the founding profile is unusually aligned with the problem, combining prior AI product work and pharmaceutical clinical-development exposure through Patricio Fernandez Weisson's roles at Evinova and Sanofi, alongside Jorn Jansen Schoonhoven's AI and operating background at IBM, Amazon, and Octopus Ventures according to company and profile materials [Cori Clinical, retrieved 2026] [Patricio Fernandez Weisson on LinkedIn: Lead Data Scientist] [Jorn Schoonhoven - Chief of Staff to EMEA GM Strategy & Market Development at Ibm - Wiza]. Second, the company is already hiring a Senior AI Engineer as of July 2026, which is a modest but real indicator that product build-out is continuing after launch rather than stopping at narrative formation [Breega, July 2026].
| Scenario | What happens | Catalyst | Why its plausible |
|---|---|---|---|
| Workflow wedge becomes system of record | Cori starts as a document and review workspace for protocol-to-submission work, then becomes the default control layer for trial-startup operations across sponsors and CROs | One or more early deployments prove that connected documents, regulatory checks, and cost visibility reduce startup friction through FPI [Cori Clinical, September 2025] | The company already positions the product around interconnected documents, workflows, and compliance logic rather than a single-point feature, which is how workflow software can expand into core infrastructure [Cori Clinical, retrieved 2026] [LinkedIn, retrieved 2026] |
| CRO distribution channel | Cori wins inside CRO teams and then rides those relationships across multiple sponsor programs, turning one enterprise sale into repeated workflow standardization | A named CRO or research institution adopts the platform across multiple study teams [Cori Clinical, retrieved 2026] | The public buyer definition explicitly includes CROs and research institutions, not only biopharma sponsors, which creates a plausible multi-account distribution path if one service provider standardizes on the workflow [Cori Clinical, retrieved 2026] |
| Compliance-aware authoring becomes the category entry point | Cori becomes the trusted AI layer for regulated trial-document generation and review, with human judgment retained but much of the mechanical work compressed | Product evidence that the platform's review engine can track interdependencies and flag alignment gaps across submission documents [Cori Clinical, retrieved 2026] | Its current positioning emphasizes preserving compliance and human control while reviewing documents against regulatory, quality, GxP, and patient-centric requirements, which is the right framing for adoption in a risk-sensitive workflow [Cori Clinical, retrieved 2026] |
The compounding mechanism is straightforward if the product works as described. Each trial adds structured knowledge about how protocols, amendments, regulatory packets, and supporting documents relate to one another. Cori says its platform adapts to protocol, geography, and documentation, tracks interdependencies between documents, and applies regulatory logic while leaving final judgment to the team [Cori Clinical, retrieved 2026]. If that functionality proves reliable in production, every successful deployment should improve templates, review pathways, and trust in the system, which in turn makes expansion into adjacent startup tasks easier. This is less a consumer-style network effect than an enterprise learning curve and workflow lock-in: once teams author, review, and reconcile trial-startup documents in one environment, the switching cost is created by accumulated process logic rather than raw data volume alone.
The size of the win is hard to quantify from public evidence because no credible market-sizing source or direct comparable is supplied in the record. That limitation should be stated plainly. Still, if the strongest scenario plays out and Cori becomes a standard workflow layer across sponsors and CROs for trial startup, the outcome could support venture-scale value creation because the product sits near a regulated, recurring, enterprise decision flow rather than a one-off services engagement (scenario, not a forecast) [Cori Clinical, September 2025] [Cori Clinical, retrieved 2026]. The more concrete public marker today is strategic fit, not valuation math: a company that becomes embedded in protocol-linked authoring, review, and submission readiness would be building into a part of clinical development that large software, CRO, and pharma-adjacent platforms already care about deeply.
Company-stated, unverified -- This section relies primarily on company materials and limited third-party corroboration, with upside analysis framed as conditional rather than observed.
Sources
Public sources
[Cori Clinical, retrieved 2026] AI for clinical trials · Cori Clinical | https://www.cori-clinical.com/
[StartupSeeker, retrieved 2026] Cori Clinical | StartupSeeker | https://startup-seeker.com/company/cori-clinical~com
[PitchBook, retrieved 2026] Cori Clinical 2026 Company Profile: Valuation, Funding & Investors | PitchBook | https://pitchbook.com/profiles/company/820169-02
[Cori Clinical, September 2025] Announcing Cori Clinical | https://www.cori-clinical.com/launchingcori
[Breega, July 2026] Senior AI Engineer | https://jobs.breega.com/jobs/8151224-senior-ai-engineer-cori
[LinkedIn, retrieved 2026] Jorn Jansen Schoonhoven - Co-Founder @ Cori Clinical | https://uk.linkedin.com/in/jornjansenschoonhoven
[FundraisingFox] Cori Clinical | https://fundraisingfox.com/companies/cori-clinical
[Patricio Fernandez Weisson on LinkedIn: Lead Data Scientist] Patricio Fernandez Weisson on LinkedIn: Lead Data Scientist | https://www.linkedin.com/posts/patricio-fernandez-weisson-_cori-clinical-announcing-cori-clinical-activity-7340685388040101892-GPon
[Jorn Schoonhoven - Chief of Staff to EMEA GM Strategy & Market Development at Ibm - Wiza] Jorn Schoonhoven - Chief of Staff to EMEA GM Strategy & Market Development at Ibm - Wiza | https://www.wiza.co/d/ibm/50d5/jorn-schoonhoven
Articles about Cori Clinical
- Cori Clinical's AI Platform Takes Aim at the Clinical Trial Backoffice — A team of former AstraZeneca, Sanofi, and IBM data leaders is building a workspace to connect documents, decisions, and costs from protocol design to first patient in.